Taxol Recommended For Second Line Therapy In Platinum-Resistant Metastatic Ovarian Cancer
In Brief: Hammond Resigned As ACS Officer; Wykoff Slated To Direct FDA Special Populations Office
Cancer society, In Major Restructure, Forms New Executive Committee, Bylaws
Mass. Passes Tobacco Tax, ACS Lauds Victory Over Cigarette Industry
DCE To Provide $3.4 Mil. For Follow-Up Of DES Daughters; Board k’s Tw RFAs, Contracts
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - Brian Wolpin celebrates FDA approval of daraxonrasib in pancreatic cancer as the future of the field
- FDA advisory committee votes in favor of Galleri approval, but calls for removal of “early” detection claims
Clinical benefit will not be considered for approval, FDA says - Trump weighs—and abandons—an executive order that would give OMB veto power over NIH grants
